1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 08-PIR-03, NCT00856375
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-C80405, C80405, SWOG-C80405, NCT00265850
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0600, S0600, CALGB-SWOG-S0600, ECOG-SWOG-S0600, CAN-NCIC-SWOG-S0600, NCCTG-SWOG-S0600, NCT00499369
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10262, EudraCT 2007-000820-42, NCT00561470
|
|
5.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20080259, NCT00911170
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 3c-03-19, NCT00159484
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: VU-VICC-GI-0622, VICC-GI-0622, 6980, NCI-6980, NCT00397384
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: H-22706, NCT00390182
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0445, NCT00492817
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTCT 06-11, NCT00493883
|
|
11.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID02-446, NCT00508443
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GI05-102, NCT00522665
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: DFCI-07070, 07-070, 7881, NCT00551421
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA182-025, 2007-005097-31, NCT00594984
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0706002781, ACS IRG 58-012-49, NCT00730158
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060447, NCT00788957
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20070411, NCT00819169
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KRN330-US-02, NCT00838578
|
|
19.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR015580, NCT00841191
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 4265, NCT00849550
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ITL-002-CRYO, NCT00861107
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BUS278T, NCT00867334
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA191-006, EUDRACT: 2009-013766-78, NCT00908024
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DEBIRI # 09.0034, UL2008.1 Revision 3.1, NCT00932438
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3160A6-2208, NCT00959946
|
